High-dose Methotrexate for Bone Cancer

This trial explores whether children, adolescents, and young adults with newly diagnosed high-grade osteosarcoma can safely leave the hospital at slightly higher methotrexate levels after their usual high-dose methotrexate chemotherapy. The researchers aim to determine if this change affects side effects or leads to hospital re-admission within a week. Additionally, the trial seeks to create patient-specific tumor models from samples to aid future research. Participants must have a confirmed diagnosis of high-grade osteosarcoma and be undergoing standard chemotherapy treatment. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial does not specify if you must stop taking your current medications, but you cannot take drugs that interfere with methotrexate clearance. Check with the trial team to see if your medications are on the list of those that interfere.

Research has shown that high-dose methotrexate is usually well-tolerated by people with osteosarcoma, a type of bone cancer. In a study with 33 patients, this treatment proved effective and could be used safely. However, serious side effects, such as kidney and liver problems, require careful monitoring.

Another study found that following specific guidelines helps ensure the safe use of high-dose methotrexate, reducing the risk of severe side effects. This is why patients in trials receive close monitoring.

Researchers are excited about this trial because it explores a new approach to managing high-dose methotrexate (HD-MTX) for bone cancer, specifically osteosarcoma. Unlike traditional protocols where discharge is based on fixed timeframes, this trial adjusts discharge timing based on individual serum methotrexate levels and renal function. This personalized approach has the potential to improve patient safety by allowing earlier discharge without compromising treatment efficacy, which could lead to better quality of life during treatment.

Research has shown that high-dose methotrexate (HDMTX) significantly improves survival rates for people with osteosarcoma, a type of bone cancer. Some studies report that about 61.5% of patients survive for at least five years, with 54.8% remaining disease-free during that period. HDMTX appears to be more effective in younger patients compared to adults. In this trial, participants will receive standard-of-care MAP chemotherapy, including HDMTX, with hospital discharge based on serum methotrexate threshold levels. Overall, incorporating HDMTX into treatment plans has led to better outcomes for many osteosarcoma patients, making it a promising option for treating this cancer.³⁵⁶⁷⁸